Scientists at the Yong Loo Lin School of Medicine, (NUS Medicine), have identified a molecular switch that helps aging brains ...

A new study by cell biologists at the University of California, Santa Cruz, suggests that an early first pregnancy may ...

Summit Therapeutics plc (NASDAQ:SMMT) remains part of biotechnology sector discussions as nasdaq index appears in broader market narratives highlighting companies engaged in clinical-stage drug ...

Radiotherapy is one of the main treatment forms for cancer. Among its most common side effects is skin damage, right up to chronic inflammation and fibroses. At present, such long-term damage can only ...

As the Trump administration continues to pivot away from vaccinations, it is pushing for the development of new antiviral therapies via the launch of a $100 million competition. | While the Trump ...

The protein Dickkopf 3 plays a key role in the development of radiation-induced fibroses - and could be a promising target ...

Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer ...

A new study by cell biologists at the University of California, Santa Cruz, suggests that an early first pregnancy may protect ...

For years, sustainability has been treated as a narrative exercise. Companies publish targets, regulators issue frameworks, and auditors sign off on methodologies that rely heavily on trust. The ...

New study reveals a central role of selenoprotein GPX3 in attenuating acute kidney injury Renal ischemia–reperfusion injury ...

Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be ...

Novo Nordisk operates in the pharmaceutical sector, with core franchises in diabetes care and obesity care supported by a ...